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Clofilium was studied in three experimental models. In non-ischemic and chronically infarcted canine hearts, 
clofilium (0.5-2 mg/kg) produced a dose-dependent increase in electrical ventricular fibrillation threshold (VFT), but 
prolonged the effective refractory period (ERP) of normal myocardium in only the non-ischemic heart. When 
chronically infarcted hearts were subjected to programmed electrical stimulation, 1 mg/kg of clofilium inhibited the 
re-induction of either ventricular tachycardia or ventricular fibrillation in 5 of 6 animals and slowed the rate of the 
induced tachycardia in the sixth. Clofilium, however, failed to alter ventricular refractory periods of normal 
myocardium at either twice diastolic threshold current (176 _+ 5 ms control vs. 187 + 9 ms post-clofilium, P > 0.05) or 
at 10 mA (134 _+ 6 ms control vs. 137 + 13 ms post-clofilium, P > 0.05). In addition, chronic administration of 
clofilium (2 mg/kg, i.v., followed by 1 mg/kg every 12 h) was ineffective in decreasing mortality in a canine model of 
sudden coronary death. Of 10 saline-treated conscious animals subjected to an electrically-induced intimal lesion of the 
left circumflex coronary artery in the presence of a previous ischemic insult, all 10 died suddenly of ventricular 
fibrillation within 173 + 45 min after current application. Under similar conditions, 7 clofilium-treated animals died 
suddenly within 249 _+ 88 min (P > 0.05) after current application while 3 animals survived (P > 0.10). Clofilium did, 
however, elevate the effective refractory period in these animals (150 _+ 3 ms saline-treated vs. 195 _+ 7 ms clofilium- 
treated). It is concluded from our data that there is little relationship between clofilium's electrophysiologic actions in 
normal myocardium and antiarrhythmic effects. Furthermore, simple prolongation of refractoriness in normal 
non-ischemic myocardium may be insufficient for the prevention of ventricular fibrillation which develops in response 
to a transient ischemic event superimposed on a chronically injured myocardium. 
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1. Introduction 
There has been recent interest in the develop- 
ment  and use of pharmacologic agents for the 
prevent ion of sudden coronary death. The /~- 
adrenergic receptor antagonists  timolol (Norwegian 
Mult icenter  Study Group,  1981), metoprolol  
(Hja lmarson et al., 1981), and propranolol  (Beta- 
Blocker Heart  Attack Study Group,  1981) have 
been reported to reduce the risk of sudden coronary 
death after myocardial  infarction.  The quaternary  
a m m o n i u m  adrenergic blocking agent bre tyl ium is 
0014-2999/85/$03.30 © 1985 Elsevier Science Publishers B.V. 
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effective in preventing ventricular fibrillation in 
both experimental animals (Bacaner, 1968; Bacaner 
and Schrienmachers, 1968; Kniffen et al., 1975; 
Cervoni et al., 1971) and man (Holder et al., 1977; 
Sanna and Arcidiacono, 1973). Another quaternary 
ammonium agent, pranolium, has been reported to 
reduce the incidence of ventricular fibrillation in 
experimental animals (Eller et al., 1983). Clofilium, 
a third drug of the quaternary ammonium type 
with electrophysiologic and potential antifibrilla- 
tory actions, has been investigated recently (Stein- 
berg and Molloy, 1979; Steinberg et al., 1981). 
Additional electrophysiologic studies using this 
drug are appropriate to correlate clofilium's re- 
ported in vitro actions and its potential in vivo 
antiarrhythmic and antifibrillatory effects. 
In this report we examine the effect of clofilium 
on: (1) the ventricular fibrillation threshold in an 
anesthetized, previously infarcted canine prepara- 
tion; (2) programmed electrical stimulation in 
anesthetized, previously infarcted dogs; and (3) 
ventricular fibrillation in a conscious canine model 
of sudden coronary death. 
2. Materials and methods 
2.1. Production of myocardial infarction 
Male mongrel dogs were anesthetized with in- 
travenous (i.v.) pentobarbital (30 mg/kg) ,  in- 
tubated, and ventilated with room air. The heart 
was suspended in a pericardial cradle after ex- 
posure by means of a left lateral thoracotomy at 
the fifth intercostal space. The left anterior de- 
scending coronary artery (LAD) was separated 
from the surrounding tissue at or just below the 
level of the tip of the left atrial appendage. A 
critical stenosis was produced by tying a ligature 
around both the vessel and a 19 g needle and then 
withdrawing the latter. The vessel was then oc- 
cluded using a snare formed from a loop of silastic 
tubing passed through a flared polyethylene tube. 
After 90 min of occlusion, the snare was released 
allowing reperfusion of the vessel through the criti- 
cal stenosis. The pericardium was then loosely 
tied, the chest incision closed, and the dogs al- 
lowed to recover. Appropriate antibiotic therapy 
was administered during the recovery phase. 
2.2. Determination of the ventricular fibrillation 
threshold (VFT) 
Seven normal and seven previously infarcted 
(4-7 days) male mongrel dogs weighing between 12 
and 14 kg were anesthetized with sodium pento- 
barbital (30 m g / k g  i.v.), intubated, and ventilated 
with room air at a rate and tidal volume which 
maintained normal blood gases and pH. The heart 
was exposed via a left thoracotomy at the fourth 
or fifth intercostal space and suspended in a peri- 
cardial cradle. An acrylic plaque containing 2 
silver-silver chloride electrodes (1 mm diameter, 3 
mm apart) were sewn to the surface of the heart in 
the interventricular septum adjacent to the right 
ventricular outflow tract for the determination of 
VFT. A second acrylic plaque electrode was sewn 
to the heart in an area of tissue perfused by the 
left circumflex coronary artery. This electrode was 
used for the determination of the excitation 
threshold and the Q-EG interval (time in ms from 
the beginning of the Q-wave to the peak of the 
ventricular electrogram, i.e., conduction time or 
CT). A bipolar plunge electrode (insulated stain- 
less steel 25 g wire, 4 mm long, 2 mm apart) was 
placed high in the left ventricle for determination 
of the effective refractory period (ERP). For all 
VFT studies, the ERP was measured at twice 
diastolic threshold current. In addition, a small 
bipolar plaque electrode was attached to the left 
atrial appendage for left atrial pacing. All electro- 
physiologic measurements were made in normal, 
non-infarcted tissue regardless of whether or not 
the animal had previously undergone myocardial 
infarction. For most experiments, the heart was 
paced at a constant rate during the measurement 
of the electrophysiologic parameters 
VFT was measured by delivering electrical cur- 
rent to the heart through the VFT electrode using 
a Grass $88 stimulator coupled to a Grass CCU-1A 
constant current unit and an SIU-5 stimulus isola- 
tion unit. A Tektronix model 565 oscilloscope with 
a type 3A8 operational amplifier was used to 
trigger the ventricular stimulus from the peak of 
the R-wave of the Lead II ECG. The triggering 
stimulus was delayed 50 ms after R activation so 
that the impulse train scanned the T-wave. Cur- 
rent was delivered every 6-8 beats using a 200 ms 
train of 4 ms pulses at a frequency of 60 Hz. Each 
current level was tested 3 times before moving on 
to the next highest current. An increasing amount 
of current was given until the animal fibrillated, at 
which time defibrillation was accomplished within 
15-20 s using a Physio-control series 70 DC de- 
fibrillator. 
Blood pressure via a cannulated carotid artery 
and the Lead II ECG were monitored continu- 
ously on a Grass model 7 polygraph. Drug injec- 
tions were made through a cannulated external 
jugular vein. 
For the determination of the Q-EG interval, 
both the Lead II ECG and the ventricular electro- 
gram were displayed at high sweep speed (10 
ms/division) on a Tektronix 5111 storage oscillo- 
scope and the time between waveforms measured. 
After two control determinations (separated by 
1 h) of all parameters each dog received sequential 
and cumulative doses of 0.5, 1.0 and 2.0 m g / k g  of 
clofilium i.v., each dose being separated by 1 h. 
One h after drug administration the electrophysio- 
logical parameters were measured again prior to 
administration of the next higher dose. After the 
last VFT determination, animals were not defibril- 
lated and the experiment was concluded. 
2.3. Programmed electrical stimulation 
Seven dogs weighing between 12 and 17 kg 
were infarcted as described above and allowed to 
recover for 4 to 7 days. On the day of the experi- 
ment, each dog was reanesthetized with 30 m g / k g  
of sodium pentobarbital, intubated, and mechani- 
cally ventilated with room air. Cannulae were 
placed in the left common carotid artery for mea- 
surement of blood pressure and in the left external 
jugular vein for injection of drugs. Blood pressure, 
Lead II ECG, and heart rate derived from the 
ECG were monitored continuously throughout the 
experiment on a Grass model 7 polygraph and the 
ECG was stored on magnetic tape (Lockheed Store 
4D) for later analysis. The chest was opened at the 
fourth or fifth intercostal space, the heart exposed 
and suspended in a pericardial cradle. Pro- 
grammed electrical stimulation was performed in a 
manner similar to that of Michelson et al. (1980). 
Briefly, a single plunge wire electrode (0.1 mm 
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diameter silver wire, Teflon coated except at the 
tip) was inserted into the left ventricle in the area 
of the right ventricular outflow tract at, or slightly 
below, the level of the previous LAD occlusion in 
normal tissue at the border of the region of infarc- 
tion. The electrode was connected to the cathode 
of a Grass constant current unit (CCU-1A) which 
was in turn connected to the S 2 output of a Grass 
$88 stimulator through a stimulus isolation unit 
(Grass SIU-5). The anode of the constant current 
unit was connected to the rib retractors which 
provided a contact surface area of 23 cm 2. A 
Tektronix model 565 oscilloscope with type 3A8 
operational amplifier was used to trigger the 
ventricular stimulus from the R-wave of the Lead 
II ECG. Using this system, 1, 2 or 3 premature 
stimuli (4 ms) could be inserted at timed intervals 
after the R wave. 
Each dog was scanned initially with 3 prema- 
ture beats at twice diastolic threshold current with 
R - S  2 intervals ranging from 350 ms to the refrac- 
tory period and $2-S 3 : $3-S 4 intervals ranging from 
200 to 125 ms. If sustained ventricular tachycardia 
(VT) or ventr icular  fibrillation could not be in- 
duced, the cathodal electrode was moved down the 
LAD distribution toward the apex of the heart or 
laterally across the surface of the left ventricle at 
the level of the LAD occlusion. Most dogs (4) 
required testing of only 1 site but no more than 6 
sites were required in any dog (1 dog). Once an 
arrhythmia could be induced in a dog, the strength 
interval relationship for that site was determined. 
The current was set at diastolic threshold and the 
interval was reduced from 300 ms in 10 ms incre- 
ments until the stimulus failed to result in a prop- 
agated beat. Then the current was increased until a 
propagated response could once again be ob- 
tained, after which the interval was decreased in 5 
ms increments. Current was increased in 0.01 mA 
increments from threshold to 0.1 mA, in 0.05 mA 
increments from 0.1 to 1 mA, and in 0.5 mA 
increments from 1 to 10 mA. Data  are presented 
as the refractory periods at both twice diastolic 
threshold current and at 10 mA. In both cases the 
value represents the longest interval at that par- 
ticular current that failed to result in a propagated 
response. 
After determining the strength interval relation- 
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ship, the stimulus current was reset to twice di- 
astolic threshold and the precise parameters for 
incuding each animal determined. Once the 
arrhythmia could be induced reproducibly (at least 
3 times), the animal was given 1 ml of 0.9% NaC1 
(saline) for each kg of body weight and allowed to 
stabilize for 45 min to 1 h. The ability to induce 
the arrhythmia was then re-tested, after which 
each animal was given clofilium, 1 m g / k g  i.v. (in 
saline, pH 7.3-7.4), and again allowed to stabilize 
for 45 min to 1 h. The strength interval relation- 
ship was then redetermined and the animals 
retested for inducibility of the arrhythmia. Some 
animals were tested further at current intensities 
greater than twice diastolic threshold and with 
subsequent doses of clofilium. 
At the termination of the experiment, each 
animal was sacrificed by excision of the heart. 
Cannulae were then inserted in the left anterior 
descending coronary artery at the site of the previ- 
ous occlusion and into the root of the aorta. The 
hearts were then stained by perfusing, at equal 
pressure (100 mmHg),  Evans blue (0.5% w / v )  
through the aortic root and triphenyltetrazolium 
(1% w / v )  in 0.01 M potassium phosphate buffer 
into the LAD. After rinsing with tap water, the 
hearts were sliced in bread-loaf fashion from apex 
to base and the amount of infarcted tissue (un- 
stained), the tissue at risk of infarction (stained 
brick red), and the remaining left ventricular mass 
(stained blue), were determined gravimetrically. 
2.4. Canine model of sudden coronary death 
The antifibrillatory action of clofilium was 
studied in a new, recently described, canine model 
of sudden coronary death (Patterson et al., 1982). 
Briefly, myocardial infarction was produced as 
described above in 20 dogs weighing between 18 
and 22 kg. During the surgical procedure, the left 
circumflex coronary artery was exposed approxi- 
mately 1 cm from its origin and the 3 mm tip of a 
25 g needle which had previously been attached to 
a length of 30 g silver wire, was inserted into the 
lumen of the artery. The wire was then secured to 
the epicardial surface of the heart with 3-0 suture. 
A bipolar plunge electrode (25 g insulated stainless 
steel, 4 mm long and 3 mm apart) was inserted 
into the interventricular septum in the area of the 
right ventricular outflow tract, approximately 1 cm 
above the level of the LAD occlusion in an area 
bordering the region of infarct. Silver disc elec- 
trodes were implanted subcutaneously (s.c.) to ap- 
proximate locations for recording the Lead II ECG. 
A cannula was inserted into the left jugular vein. 
The chest incision was closed and the animals 
allowed to recover. The ECG of each dog was 
monitored daily and when sinus rhythm resumed 
(usually 48-72 h after surgery) animals were rando- 
mized to either control or clofilium treatment 
groups. Control animals received 10 ml saline and 
clofilium-treated animals received an initial i.v. 
dose of 2 m g / k g  followed by additional doses of 1 
m g / k g  every 12 h. Programmed electrical stimula- 
tion was performed after 24 h of treatment, just 
prior to the next scheduled dose. Animals were 
studied while conscious and resting comfortably in 
a sling. One, two or three premature ventricular 
stimuli (4 ms pulses at twice diastolic threshold 
voltage) were introduced via the electrode in the 
interventricular septum in a manner similar to that 
described above. The procedure was performed 
until non-sustained ventricular tachycardia (self- 
terminating ventricular tachycardia lasting longer 
than 3 beats) or sustained ventricular tachycardia 
was produced in triplicate. A rigorous atempt at 
production of inducible arrhythmias was avoided 
in order to circumvent the induction of ventricular 
fibrillation. 
After completion of programmed electrical 
stimulation, the scheduled dose of clofilium (1 
mg /kg )  or saline (10 ml) was administered. An 
anodal current of 150 FA was then applied to the 
intimal surface of the left circumflex coronary 
artery by connecting the previously implanted wire 
to a 9 V battery and a variable potentiometer. The 
Lead II ECG was recorded via radiotelemetry on a 
Grass model 7 polygraph. Throughout the dura- 
tion of intimal stimulation, the animals were am- 
bulatory as all the necessary equipment was secured 
in the pouch of a nylon mesh vest. 
At the time of ventricular fibrillation or the 24 
h end point, animals were anesthetized and their 
hearts were excised. The left circumflex coronary 
artery was examined for the presence of intimal 
damage and thrombus formation. Hearts were then 
sectioned in bread-loaf fashion from apex to base 
and incubated at 37°C in 0.5% triphenyltetra- 
zolium in 0.01 M phosphate buffer, pH 7.4. Infarct 
size was determined gravimetrically and expressed 
as a percentage of the total left ventricular mass. 
The Unit for Laboratory and Animal Medicine 
of the University of Michigan observed and ap- 
proved the experimental protocols. Experiments 
were performed according to the 'Guiding Princi- 
ples in the Care of Laboratory Animals'  as out- 
lined by the American Physiological Society. 
2.5. Data analysis 
Data are expressed as the means + S.E.M. Dif- 
ferences between doses of clofilium in the VFT 
study were assessed using 2-way ANOVA and 
Scheffe's test (Dixon and Massey, 1969). In the 
programmed electrical stimulation study, dif- 
ferences in electrophysiological parameters after 
clofilium administration were analyzed using the 
paired t-test. Fisher's exact test was used to de- 
termine whether there was a difference in survival 
between clofilium and saline-treated animals in the 
sudden death experiments and Student's unpaired 
t-test was used to determine significant differences 
between means of saline-treated and clofilium- 
treated groups of animals. For all tests, the null 
hypothesis was rejected only if the probability of 
the calculated statistic was less than 0.05, 
3. Results 
3.1. Effect of clofifiurn on electrical ventricular fibril- 
lation threshold 
Figures 1 and 2 summarize the effect of 0.5, 1 
and 2 m g / k g  doses of clofilium on both VFT and 
the effective refractory period in normal and 
chronically infarcted canine hearts. In normal, 
non-infarcted hearts, clofilium produced a maxi- 
mum and sustained elevation in effective refrac- 
tory period with the smallest dose (0.5 mg/kg) ,  
but failed to increase VFT significantly until after 
administration of the highest dose (2.0 mg/kg ,  fig. 
1). Conversely, in the chronically infarcted heart, 
clofilium failed to significantly increase the effec- 
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Fig. 1. Antifibrillatory action of clofilium (0, 0.5, 1.0, and 2.0 
mg/kg) in the normal non-ischemic canine heart. The upper 
panel depicts the changes in the effective refractory period (in 
ms) at twice threshold current after a control determination 
and after the three doses of clofilium. The bottom panel shows 
the elevation in electrical VFT produced by clofilium. * Sig- 
nifies significant difference from control. 
tive refractory period at any dose level while pro- 
ducing a graded increase in VFT which achieved 
statistical significance only at the 2 m g / k g  dose 
(fig. 2). Control VFT's  for both groups were not 
different (6.4 _+ 1.7 mA non-infarcted VFT vs. 9.8 
+ 3.2 mA infarcted VFT) nor were the maximum 
VFT's  after the 2 m g / k g  dose of clofilium (28.4 + 
6.4 mA non-infarcted VFT vs. 26.2 + mA in- 
farcted VFT). Figure 3 is an example of a ventricu- 
lar fibrillation threshold experiment conducted in 
a dog subject to previous myocardial infarction. 
Table 1 summarizes the remaining electrophysi- 
ological and cardiovascular actions of clofilium 
that were measured in this study. With the excep- 
tion of a modest decrease in heart rate in the 
non-infarcted animals, clofilium failed to produce 
any alterations in mean blood pressure, excitation 
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Fig. 2. Antifibrillatory action of clofilium in the chronically 
infarcted canine heart. Presentation of data similar to that in 
fig. 1. 
3.2. Effect of clofilium in dogs subject to pro- 
grammed electrical stimulation 
Tables 2 and 3 summarize the effect of clofilium 
in a canine model of programmed electrical stimu- 
lation. Of the 7 dogs originally studied, 1 animal 
fibrillated during determination of the strength 
interval relationship after clofilium administration 
and could not be revived despite vigorous direct 
heart massage and repeated cardioversion at- 
tempts. This animal is not included in the data of 
tables 2 and 3. Data from the remaining 6 animals, 
however, show that administration of 1 mg /kg  of 
clofilium was effective in either preventing the 
induction of ventricular tachycardia by pro- 
grammed electrical stimulation (5 dogs) or slowing 
the cycle length of the tachycardia (1 dog, table 2). 
This dose of clofilium, however, failed to alter 
excitation threshold or the effective refractory 
period at either twice diastolic threshold current or 
at 10 mA (table 3). Only 1 animal showed a 
substantial increase in the effective refractory 
period (table 3, dog 1) while 1 animal showed a 
small decrease in the effective refractory period at 
twice threshold current and a larger decrease at 10 
mA (table 3, animal 6). The remaining animals 
showed only minor alterations in refractoriness. 
After blocking the induced arrhythmia with 1 
m g /k g  of clofilium, 2 dogs (nos. 2 and 4) were 
tested further at 5 times diastolic threshold current 
and were found to be non-inducible even  at the 
increased stimulation current. Two other animals 
(nos. 1 and 5) were tested at 5 times diastolic 
threshold current. In animal number 5, 3 prema- 
ture beats at 5 times diastolic threshold current 
and with coupling intervals of 170, 125 and 125 ms 
produced a ventricular tachycardia with a cycle 
length of 138 ms which rapidly degenerated into 
TABLE 1 
Electrophysiologic and cardiovascular actions of clofilium in normal and chronically infarcted dogs. 
Dose of clofilium (mg/kg)  
0 0.5 1 2 
Mean blood N 92 -+ 5 a 82 _+ 6 82 -+ 7 76 + 12 
pressure I 87 _+ 6 86 -+ 4 80 _+ 3 83 -+ 3 
(mmHg) 
Heart rate N 158_+9 133+_14 b 121 +14 h 112-+17 b 
(BPM) 1 172_+8 165-+5 154-+7 2 165-+5 
Excitation N 0.097 _+ 0.019 0.254 -+ 0.129 0.151 -+ 0.039 0.302 -+ 0.176 
threshold l 0.6 -+ 0.1 2.1 _+ 1.1 2.0 + 1.0 1.5 -+ 0.4 
(mA) 
Conduction N 20 -+ 2 19 -+ 2 21 -+ 2 20 -+ 2 
time 1 31 -+ 1 31 + 1 30 -+ 1 31 -+ 1 
(ms) 
a Mean + S.E.M., n = 7 for both normal (N) and chronically infarcted (I) groups. 6 Significantly less than without clofilium; P < 0.05 
by 2-way ANOVA and Scheffe's test. 
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Fig. 3. An example of the antifibrillatory action of clofilium in a chronically infarcted canine heart. In this animal, 1.0 m g / k g  of 
clofilium produced the largest increase in VFT to a value of 26.5 mA while the 0.5 m g / k g  dose produced the largest increase in the 
ERP. 
ventricular fibrillation. Further administration of 2 
mg /kg  of clofilium to this dog failed to prevent 
induction of the ventricular tachycardia, but in- 
creased the cycle length to 153 ms and prevented 
the degeneration of the ventricular tachycardia to 
ventricular fibrillation. The remaining animal (no. 
1) responded to programmed electrical stimulation 
at 5 times threshold current and with 3 ventricular 
stimuli (230, 155, 155 ms) leading to ventricular 
tachycardia which degenerated into ventricular 
fibrillation. This dog received no further clofilium. 
However, prior to clofilium, and at twice threshold 
current, this animal required only 2 premature 
stimuli at coupling intervals of 180 and 165 ms. 
After 1 mg /kg  of clofilium even 3 premature 
stimuli at twice threshold current and at intervals 
of 230, 140 and 140 ms failed to induce a ventricu- 
lar tachycardia so that clofilium afforded this 
animal a considerable degree of protection against 
the production of the tachycardia. 
Staining of the hearts from all 7 dogs revealed 
mottled, non-confluent subendocardial infarcts 
that occasionally extended transmurally. Average 
TABLE 2 
Antiarrhythmic actions of clofilium in dogs subject to pro- 
grammed electrical stimulation. 
Dog Pre-clofilium Clofilium (1 mg /kg )  
Arrhythmia Cycle Arrhythmia Cycle 
length (ms) length (ms) 
1 V-Tach a 200 
2 V-Tach Fib a 125 
3 V-Tach 168 
4 V-Tach 158 
5 V-Tach Fib 109 







a V-Tach, sustained ventricular tachycardia; Fib, fibrillation. 
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Fig. 4. Effect of clofilium on survival in a canine model of 
sudden coronary death. Clofilium failed to exert any significant 
protection against sudden death in this animal model when 
administered as a 2 m g / k g  loading dose followed by 1 m g / k g  
every 12 h for 24 h. Data  were analyzed using Fisher's exact 
test. 
infarct size in these animals was 17.4 _+ 1.9% of the 
total left ventricle. The single animal that fibril- 
lated and could not be revived had the largest 
infarct of any animal: 25.8% of the left ventricle. 
3.3. Effect of clofilium in a canine model of sudden 
coronary death 
In concious ambulatory dogs, subjected to acute 
ischemia at a site remote from a previous infarc- 
tion, clofilium was ineffective in preventing sud- 
den death due to ventricular fibrillation. Figure 4 
depicts the mortality curves and table 4 sum- 
marizes the electrophysiologic changes, infarct size, 
and thrombus mass data obtained from saline- 
treated control animals and animals treated 
chronically with clofilium. Of 10 dogs given 2 
mg/kg  clofilium followed by 1 mg/kg  for 12 h, 7 
dogs succumbed to ventricular fibrillation within 
an average of 249_+ 88 min after application of 
150 ~A to the intimal surface of the left cir- 
cumflux coronary artery. Each of the 10 saline- 
treated animals fibrillated (173 _+ 45 min-post 150 
/~A) and the difference between these 2 groups of 
animals is not significant (P > 0.10, fig. 3). 
Clofilium did produce a significant prolonga- 
tion of the effective refractory period (195 + 7 ms 
in clofilium-treated vs. 150_+ 3 ms in saline con- 
trols, P < 0.05). However, this was not associated 
with a decrease in mortality in the clofilium-treated 
dogs suggesting that increasing refractoriness alone 
was not sufficient to prevent ventricular fibrilla- 
tion in these animals. 
Of the remaining parameters measured, clofi- 
lium-treated animals appeared slightly less suscep- 
tible to the production of sustained and non-sus- 
tained ventricular tachycardia, but this was not 
statistically significant. There were no significant 
differences between the thrombus  mass, infarct 
size, or the time to electrocardiographic changes 
noted in table 4 in clofilium-treated and saline- 
treated dogs. These data suggest that clofilium 
exerted its principal electrophysiologic effect of 
prolongation of the effective refractory period, but 
failed to exert a significant protective antifibrilla- 
tory effect. 
TABLE 3 
Electrophysiological actions of clofilium in dogs subject to programmed electrical stimulation. 
Dog Excitation threshold (mA) Effective refractory period 
(ms; twice threshold mA) 
Effective refractory period 
(ms; 10 mA) 
Pre-clofilium Post-clofilium Pre-clofilium Post-clofilium Pre-clofilium Post-clofilium 
1 0.22 0.06 171 228 125 195 
2 0.05 0.07 176 175 125 115 
3 0.06 0.05 169 175 135 130 
4 0.06 0.08 181 185 150 145 
5 0.06 0.13 160 167 115 115 
6 0.11 0.11 198 190 155 120 
Mean 
± S.E.M. 0.09 ± 0.03 0.08 ±0.01 176± 5 187 ± 9 134± 6 137 ± 13 
TABLE 4 
Action of clofilium in a canine model of sudden coronary 
death a. 










(% Left ventricle) 








STchange 99 +34 184 
PVB 111 +34 216 -1-41(n=8) 
VT 131 +37 213 +49(n=7) 
VF 173 +45 249 +88(n=7) 
LAD 19 + 3 14 + 3 
:t:30 
LCX 33(n=1) 16 + 4 (n=3)  
7.5_ 2.1 19.1+ 5.9 
10/10 7/10 
a NI, non-inducible; NSVT, non-sustained ventricular tachy- 
cardia; SVT, sustained ventricular tachycardia; PVB, prema- 
ture ventricular beats; VT, ventricular tachycardia; VF, 
ventricular fibrillation; LAD, left anterior descending coronary 
artery; LCX, left circumflex coronary artery, b p < 0.05 by 
non-paired t-test; n = 10 except where otherwise noted. 
One surprising and unexpected finding in this 
study was that clofilium appeared to occasionally 
produce ventricular arrhythmias. While these were 
not quantitated, 2 of the 7 anesthetized dogs sub- 
jected to programmed electrical stimulation and 6 
of the 10 conscious dogs used in the sudden death 
model responded to clofilium administration with 
ventricular arrhythmias, characterized by both 
single and multiple multifocal premature com- 
plexes and occasionally short runs of spontaneous 
non-sustained ventricular tachycardia. These 
arrhythmias occurred in two dogs anesthetized 
acutely after administration of clofilium, and also 
were present in the conscious animals 12 h after 
clofilium administration. 
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4. Discuss ion 
Mortality as a result of sudden coronary death 
represents a major cause of loss of life in the 
United States today. Estimates are that as many as 
199 000 to 386 000 individuals (Doyle, 1979) may 
die suddenly each year. Because most of these 
deaths result from ventricular fibrillation sec- 
ondary to ischemic heart disease (Peter et al., 
1980), much experimental effort has been aimed at 
finding effective pharmacologic agents for the pre- 
vention of ventricular fibrillation. Clinical trials 
with the fl-adrenergic blocking agents timolol, 
metoprolol and propranolol have demonstrated 
that these drugs are capable of reducing mortality 
due to sudden coronary death in individuals with a 
previous myoardial infarction. The precise mecha- 
nism by which this is accomplished, however, is 
not yet certain, although fl-adrenergic blockade 
most likely plays an important role. 
Previous investigators have found that the 
adrenergic neuronal blocking agent, bretylium, was 
effective in elevating the electrical ventricular 
fibrillation threshold in animals (Bacaner, 1968; 
Bacaner and Schrienemachers, 1968; Kniffen et 
al., 1975; Cervoni et al., 1971) and later work 
demonstrated bretylium to be efficacious as an 
antifibrillatory agent in man (Holder et al., 1977; 
Sanna and Arcidiacono, 1973). The mechanism of 
bretylium's antifibrillatory action, however, was 
believed not to be due to its adrenergic neuronal 
blocking properties since: (1) another adrenergic 
neuron blocking drug, guanethidine, was ineffec- 
tive in elevating ventricular fibrillation threshold 
(Baraner, 1968; Cervoni et al., 1971); (2) in vitro 
electrophysiologic studies demonstra ted  that 
bretylium exerted its primary electrophysiologic 
property (prolongation of action potential dura- 
tion and tissue refractoriness) despite prior sym- 
pathetic blockade with either reserpine pretreat- 
ment (Wit et al., 1970) or immunosympathectomy 
(Namm et al., 1975); and (3) the in vivo electro- 
physiologic and antifibrillatory actions of brety- 
lium were intact despite prior reserpine adminis- 
tration (Cervoni et al., 1971) or surgical denerva- 
tion (Waxman and Wallace, 1972). The above 
observations suggest that prolongation of the 
ventricular action potential duration (and ventric- 
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ular refractoriness) is bretylium's principal mecha- 
nism of action. Drugs which similarly prolong 
ventricular refractoriness may be effective in pre- 
venting ventricular fibrillation or reentrant ar- 
rhythmias (Steinberg and Molloy, 1979; Moe, 
1975). Others have suggested that ventricular 
fibrillation is fundamentally a reentrant-type 
arrhythmia (Moe, 1975) where prolongation of the 
reentrant pathway by increasing refractoriness 
represents a reasonable approach to the prevention 
of ventricular fibrillation. 
Recently, the new quaternary ammonium com- 
pound, clofilium, has been found to prolong ac- 
tion potential duration and myocardial refractori- 
ness (Steinberg and Molloy, 1979; Steinberg et al., 
1981). Clofilium produces a rate-dependent in- 
crease in action potential duration, increases the 
effective refractory period in proportion to the 
action potential duration, and appears to produce 
a greater increase in action potential duration in 
normal vs. acutely infarcted myocardium, thus 
decreasing the disparity in refractoriness of normal 
and infarcted tissue (Steinberg et al., 1981). 
Clofilium, however, has no effect on conduction, 
Vma X, and unlike bretylium, has no adrenergic 
neuronal blocking properties (Steinberg and Mol- 
loy, 1979). In addition to the above in vitro effects, 
clofilium has been shown to elevate electrical 
ventricular fibrillation threshold in dogs (Steinberg 
and Molloy, 1979) and prevents ventricular 
tachycardia and ventricular fibrillation in dogs 
subjected to programmed electrical stimulation 
(Michelson et al., 1981). These observations are in 
agreement with data presented in this report. 
Clofilium was fully effective, although at some- 
what higher doses than those used elsewhere 
(Steinberg and Molloy, 1979; Platia and Reid, 
1980; Greene et al., 1981; Michelson et al., 1981), 
in elevating electrical ventricular fibrillation 
threshold in both normal and previously infarcted 
canine myocardium and in preventing induced 
ventricular tachycardia and fibrillation in dogs 
undergoing programmed electrical stimulation. 
Additionally, clofilium was effective in slowing the 
rate of the tachycardia in inducible animals. 
Clofilium was not, however, effective in a re- 
cently described model of sudden coronary death 
(Patterson et al., 1982). This model overcomes 
some of the objections raised with other animal 
models of ventricular arrhythmias and fibrillation. 
It is characterized by the presence of an area of 
previous myocardial infarction and the ability of 
programmed electrical stimulation to elicit reen- 
trant ventricular arrhythmias. Drugs are evaluated 
in the conscious animal, thus eliminating the con- 
founding effects of anesthesia upon both the auto- 
nomic nervous system and the myocardial electro- 
physiologic properties. In addition, ventricular 
dysrhythmias develop spontaneously as a result of 
either a partial or complete occlusion of the left 
circumflex coronary artery by a platelet thrombus 
(Patterson et al., 1982; Romson et al., 1980), re- 
suiting in mortality rates up to 100%. When a 
similar thromboembolic lesion is produced in 
animals without previous infarction, the mortality 
is 20% (Patterson et al., 1982). Therefore, in the 
model employed in the present report, ventricular 
fibrillation, is produced by a generally non-lethal 
ischemic event. While clofilium was effective in 
increasing the duration of the effective refractory 
period over that of control animals, no significant 
decline in mortality was observed in this model of 
sudden death, although the trend for clofilium- 
treated animals was favorable. In such studies with 
small numbers of animals there is always the risk 
that the failure of clofilium treatment was due to a 
type II statistical error viz., clofilium really is 
beneficial in such a model but the use of too few 
animals failed to show a statistical benefit. While 
this is certainly a consideration it is important to 
point out that other drugs such as bretylium (Hol- 
land et al., 1983) nadolol (Patterson and Lucchesi, 
1983) amiodarone (Patterson et al., 1983) pranol- 
ium (Eller et al., 1983) and sotalol (Lynch et al., 
1985) have all been studied in an identical model 
with the same numbers of animals in each treat- 
ment group and have shown significant benefits 
when compared to appropriate vehicle control 
animals. Thus, a relative comparison would sug- 
gest that clofilium is less effective in the canine 
model of sudden death than these other agents, yet 
there is clearly a favorable trend. These pharmaco- 
logic agents, however, have multiple actions. As 
previously mentioned, in addition to increasing 
myocardial cellular refractoriness, bretylium is also 
an adrenergic neuronal blocking agent. Con- 
versely, nadolol has little effect on conduction and 
refractoriness, in myocardial tissue (Patterson and 
Lucchesi, 1982), but is a /3-adrenergic blocking 
drug (Lee et al., 1975). Pranolium (UM-272) not 
only increases cellular refractoriness, but also de- 
creases myocardial conduction both in vitro (Ro- 
sen et al., 1975) and in vivo (Gibson et al., 1978; 
Patterson and Lucchesi, 1981). Thus, the observa- 
tion that clofilium failed to exert a significant 
antifibrillatory effect in the conscious dog suggests 
that, at least in this model, the milieu of factors 
which predisposes the heart to spontaneous 
ventricular fibrillation may require greater appea- 
sement than simple prolongation of action poten- 
tial duration and refractoriness. The underlying 
electrophysiological substrate during myocardial 
ischemia which ultimately provokes ventricular 
fibrillation is most likely the sum total of many 
individual factors working in concert. Even though 
clofilium is effective in prolonging the action 
potential duration in normal and ischemic myocar- 
dium in vitro, and is able to elevate electrical 
ventricular fibrillation threshold in vivo, during 
the dynamic process which ultimately leads to 
sudden death, one or a multiple of these factors 
may overcome any beneficial effect on action 
potential duration which has been produced by 
clofilium. So, while it is difficult to draw any firm 
conclusion based on the small number of animals 
used in the sudden death study, it is clear that 
further effort should be made to determine the 
precise benefit, if any, of prolongation of refracto- 
riness in in vivo animal models of sudden coronary 
death. 
In this regard, data from our study must ques- 
tion the benefit of prolonged refractoriness by 
clofilium as it regards clofilium's antifibrillatory 
effect. We saw no clear relationship between these 
two effects. In the VFT study, in the non-ischemic 
canine heart, clofilium clearly elevated myocardial 
ERP but at a dose which had no effect on VFT. 
Conversely, in chronically infarcted animals, 
clofilium produced no significant effect on ERP of 
normal myocardium but elevated the VFT to the 
same level as in the non-ischemic canine heart. 
This may be explained partially by the fact that 
the average paced heart rate in the non-ischemic 
group was somewhat lower than the paced rate in 
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the infarcted group (163 _+ 8 vs. 190 _+ 6 beats/min,  
respectively; P < 0.05). However, in those animals 
subjected to programmed electrical stimulation, no 
change in ERP occurred after clofilium and the 
paced heart rate was 161 _+ 9 beats/min,  a value 
similar to the paced rate in the non-infarcted VFT 
group where a significant increase in ERP oc- 
curred after clofilium. As previously mentioned, 
while the ERP was prolonged in the animals 
studied under conditions which provoked sudden 
death, certainly this did not provide any protec- 
tion to this group of animals. While others have 
reported a relationship between clofilium's anti- 
arrhythmic and electrophysiologic action (Platia 
and Reid, 1980; Greene et al., 1981; Michelson et 
al., 1981), our data can not confirm this relation- 
ship. 
It should be pointed out that in no animal can 
clofilium administration be causally related to 
either ventricular fibrillation or sudden death. 
However, any further evaluation of this agent 
should be tempered with the knowledge that 
ventricular arrhythmias may be an undesirable 
side effect of therapy with clofilium. 
It should also be pointed out that limitation of 
the present study relates to the sampling sites 
chosen for electrophysiologic investigation. In gen- 
eral, sampling sites were in normal regions or 
regions bordering ischemic areas, but no direct 
measurements were made from ischemic areas. To 
the extent that ischemia generates electrophysio- 
logic disturbances in non-ischemic tissues our ob- 
servations are valid, especially since each dog was 
its own control. However, further studies in 
ischemic tissues are warranted especially since the 
apparent lack of correlation between clofilium's 
electrophysiologic and antiarrhythmic actions 
might be further clarified if ischemic tissue were 
studied. 
In summary, clofilium is a new quaternary am- 
monium antiarrhythmic agent which is capable of 
elevating electrical ventricular fibrillation threshold 
in both normal and chronically infarcted dogs and 
prevents the induction of reentrant ventricular 
arrhythmias in dogs undergoing programmed elec- 
trical stimulation. It does not, however, signifi- 
cantly reduce mortality in a canine model of sud- 
den coronary death at the dose studied. Although 
6(1 
c lo f i l i um s h o w e d  a n t i a r r h y t h m i c  ac t iv i ty  in the  
m o d e l s  s tud ied ,  a s ign i f i can t  p r o t e c t i v e  e f fec t  was  
n o t  o b s e r v e d  in t he  s u d d e n  d e a t h  mode l .  Th i s  m a y  
i n d i c a t e  t ha t  a s u b t h e r a p e u t i c  d r u g  level was  
a c h i e v e d  a n d  a smal l  i n c r e m e n t  in d o s e  or  c h a n g e  
in s c h e d u l e  m i g h t  s h o w  g rea t e r  ef f icacy.  Also ,  
a n e s t h e t i c  e f fec t s  m a y  a lso  a c c o u n t  for  this  d is-  
c r e p a n c y .  T h e r e  is, h o w e v e r ,  a sugges t i on  t h a t  a 
c h a n g e  in t he  E R P  of  n o r m a l  m y o c a r d i u m  i n d u c e d  
by  c lo f i l i um is no t  the  sole m e c h a n i s m  of  a c t i on  o f  
th is  drug.  
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